Novartis drops NHS legal protest over Lucentis; Non-profit launches patent-challenge aid;

@FiercePharma: Novartis drops its legal case against U.K. doc group that nixed Lucentis. The group changed policy after Novartis cut price. More | Follow @FiercePharma

> Novartis ($NVS) will drop its legal challenge to a U.K. treatment group that avoided its eye drug Lucentis in favor of off-label Avastin use; the doctors changed their policy after Novartis offered a discount. Report

> Patent challengers have a new ally: Médecins Sans Frontiéres launched an online database to make it easier to root out faulty patent applications. Report

> India's Cipla won World Health Organization pre-qualification for its malaria drug, a big step toward launching the treatment across Asia. Report

> Rigel Pharmaeuticals ($RIGL) plans a stock offering to fund R&D and cover other corporate expenses; few details are yet available. Report

> The commonly used heart drugs known as beta blockers may be overused in many patients, a study found. Report

Medical Device News

 @FierceMedDev: Paper Dx could become even cheaper if this new research finding catches on. More | Follow @FierceMedDev

 @MarkHFierce: The U.S. breast implant market will grow modestly in the coming years, Millennium estimates, but Europe's won't. More | Follow @MarkHFierce

 @DamianFierce: Fresh off its $100M IPO, Globus Medical got FDA approval for its spinal disc implant. More | Follow @DamianFierce

> Analysts: Device market growth will outpace pharma by 2018. News

> Allergan abandons pursuit of FDA clearance for teen use of Lap-Band obesity device. Article

Biotech News

 @FierceBiotech: Special report: The Top Phase III Disasters of 2012. Report | Follow @FierceBiotech

 @JohnCFierce: First "complete virtuous circle" for crowdfunding biotech model in France. Interesting idea. Hard to pull off. Release | Follow @JohnCFierce

 @RyanMFierce: Nice to see VentiRx deal with Celgene, and a win for a biotech with small virtual staff and big potential. More | Follow @RyanMFierce

> Crowdfunding pioneers claim cash-out following biotech launch. Report

> Merck pumped about promising IIb results for once-weekly diabetes drug. Article

> Sarepta shares boom on stellar DMD trial results. Story

Biomarkers News

> Singulex heads for $86.25M flotation. Item

> RNA profiles pinpoint the course of MS. Story

> Biomarkers boost success, cut costs in breast cancer clinical trials. Article

> Singulex heads for $86.25M flotation. More

Drug Delivery News

> Pfizer pays out on Antares drug delivery tech agreement. News

> Nanoparticles getting under your skin? Maybe not, actually. Story

> Noven ADHD patch heads into Phase II. Article

And Finally... Cancer patients are often unaware of diagnostic tests that can better target their treatment. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.